Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
JAK Inhibitors
•
Dermatology
What is your approach to using topical JAK inhibitors in the management of cutaneous manifestations of rheumatic disease?
Related Questions
Have you utilized JAK inhibitors in patients on dialysis?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?
What is your approach to treatment in patients with cutaneous mastocytosis and inflammatory arthritis?
How would you approach management of a patient with longstanding history of SLE, but having active psoriasis?
Are you comfortable trying a different JAK inhibitor in patients with prior JAK inhibitor allergy?
Do you generally utilize calcium channel blockers on an as needed basis for patients with Raynaud's phenomenon?
How would you manage a patient with hidradenitis suppurativa and inflammatory arthritis (RA vs. PsA)?
How do you approach managing nausea and GI side effects when initiating methotrexate?
Would you switch azathioprine to a different immunosuppressant if a controlled patient with SLE develops melanoma and/or non-melanoma skin cancer?
Can Dupixent (dupliumab) be safely used in patients who are taking other biologics for rheumatic disease?
